Compare SYNX & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYNX | BRTX |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.3M |
| IPO Year | 2023 | 2015 |
| Metric | SYNX | BRTX |
|---|---|---|
| Price | $1.01 | $0.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 221.5K | ★ 3.4M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | $32.35 | $438.78 |
| Revenue Next Year | N/A | $21.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.19 |
| 52 Week High | $2.15 | $2.04 |
| Indicator | SYNX | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 37.05 |
| Support Level | $0.93 | $0.20 |
| Resistance Level | $1.31 | $0.31 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 33.35 | 21.02 |
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.